West Coast Antibody Therapeutics Xchange
san francisco
27 SEPTEMBER, 2022
Welcome to hubXchange’s West Coast Antibody Therapeutics Xchange 2022, bringing together executives from pharma and biotech to address and find solutions to the key issues faced in developing antibody therapeutics.
Discussion topics will cover Target Selection, Lead Identification & Optimization, Formats & Scaffolds, Bi/Multi-specifics and Emerging Technologies.
Take advantage of this unique highly interactive meeting format designed for maximum engagement, collaboration and networking with your peers.
NOTE: This will be an In-Person event
VENUE DETAILS: DoubleTree by Hilton San Francisco Airport Hotel, 835 Airport Blvd., Burlingame CA 94010-9949
Target Selection
Lead Identification & Optimization
Formats & Scaffolds
Bi/Multi-Specifics
Emerging Technologies
Target Selection
Time
Titles and Bullets
Facilitator
8:00 – 8:30am
Registration
9:05 – 10:05am
Considerations and challenges guiding target selection in the development of antibody-based therapeutics
- To which extent the therapeutic modality (conventional antibody, antibody fragment, ADC, CAR-T, RPT, etc.) affects the target selection? Since companies tends to focus on a specific biologic platforms (often with IP protection), are viable targets selected to better match the therapeutic modality, or should the target be selected upfront and the optimal therapeutic approach tailored to the antigen biology?
- To which extent a crowded competitive space affects your target selection? For example, repurposing well validated antigens (Her2, PSMA, CEA, etc.) often attracted substantial VC funding. Should the industry put more focus on novel target discovery, or exploring all the options for old targets?
- How much of your target discovery rely on external innovation through academic collaborations or joint development programs? What are the business/operational/legal challenges presented by such collaborations.
- Is de-novo target discovery part of your process? And what are the costs (time and financial), and risks associated with committing to the discovery and validation of novel targets? What techniques do you employ to discover novel targets and how do you reliably validate preclinically for its expression in patients?
Director of Research, ImaginAb
Alessandro Mascioni works as Director of Research at ImginaAb. A Los Angeles based biotech where he oversees the development of antibody fragments for use as toxic payload delivery in cancer radiotherapy. Dr. Mascioni has 12 years of experience in project leadership, target selection, and biologics discovery and development in multiple therapeutic areas with special enphasis to cancer and immuno-oncology. Before joining ImaginAb, Dr. Mascioni worked at the Pfizer Centers for Therapeutic Innovation in Boston, where he participated to the screening and evaluation of numerous external opportunities, and co-authored research proposals in collaboration with academic key opinion leaders.
10:10 – 10:40am
10:40 – 11:10am
1-2-1 Meetings/Networking Break
1-2-1 Meetings/Networking Break
11:10 – 11:20am
Morning Refreshment Break
12:20pm – 1:20pm
1:20pm – 1:50pm
Networking Lunch Break
Spotlight Presentation
1:55pm – 2:55pm
Selecting Target Pairs for Bispecific Therapeutic Antibody Development
- We see exciting bispecific therapeutic antibodies hit the clinic, but how are early target pair choices typically made?
- Do you start with a favorite bispecific format and MoA (a hammer) and go looking for a pair of targets (nails) that can be addressed effectively? Or the other way around?
- Do you start with a favorite target pair then try everything to get a BsAb to work? Or do you focus on achieving a specific biological effect and plan to try many different target pairs to get it?
- Have you identified any strategies for predicting which targets will work well as a pair based on pre-existing data for each individual target?
- Do you primarily focus on obligate bispecific mechanisms of action? Under what circumstances or with which types of targets might you consider using a bispecific molecule when a combination of mAbs could potentially do the job instead?
- If using bispecific antibodies for dual-targeting approaches, what are the key factors influencing your choice of AND versus OR binding logic gates?
CEO & Co-founder, Rondo Therapeutics
Shelley Force Aldred, Ph.D. is a serial entrepreneur and experienced drug developer. Dr. Force Aldred is CEO and co-founder of Rondo Therapeutics, a biopharmaceutical company developing bispecific therapeutic antibodies for oncology indications. Previously, she served as VP for Preclinical Development at Teneobio, a highly successful multispecific therapeutic antibody company. In the past, Dr. Force Aldred was COO and co-founder of SwitchGear Genomics, a venture-backed functional genomics platform company. Prior to founding SwitchGear Genomics, Dr. Force Aldred was a Scientific Director on Stanford’s ENCODE Project and received her Ph.D. from Stanford University
3:00pm – 3:30pm
3:30pm – 4:00pm
1-2-1 Meetings
1-2-1 Meetings
4:00pm – 4:10pm
Afternoon Refreshments
4:45pm – 5:45pm
Targets for solid malignancies – How to define the therapeutic window experimentally
Principal Investigator, Arcus Bioscience
5:45pm – 6:45pm
Closing Address & Canape/Drinks Reception
Lead Partner
Partners
Previous
Next
Antibody Therapeutics Xchange | West Coast 2022
Register